Factor IX Complex Market Size, Growth & Outlook 2026-2033

The global Factor IX Complex market is set for steady expansion from 2026 to 2033, supported by sustained demand in hemophilia B care, broader diagnosis in emerging health systems, and stronger use of plasma-derived and recombinant therapies. The market is projected to reach about $3.6 billion by 2033, rising from an estimated $2.2 billion in 2026 at a compound annual growth rate of 7.3%. Demand is shaped by the need for prophylactic treatment, better access to specialty hematology centers, and the shift toward products with more predictable dosing and improved safety profiles. Growth is also tied to payer willingness in high-income markets and improving treatment access in large middle-income countries where diagnosis rates are still rising.

From 2019 to 2025, the market moved from roughly $1.6 billion to about $2.0 billion as treatment continuity improved and more countries expanded reimbursement for bleeding disorder care. Growth was uneven across years, with 2020 and 2021 affected by care delays and logistics pressure, while 2022 through 2025 recovered on the back of outpatient infusion normalization and better hemophilia registry coverage. The 2026 base year is best viewed as a market valued near $2.2 billion, reflecting a wider mix of prophylaxis, immune tolerance use in select cases, and hospital and specialty pharmacy distribution. Between 2026 and 2033, the expected $1.4 billion gain is driven less by sheer patient volume and more by higher treatment intensity, product mix upgrades, and stronger penetration in countries where diagnosis still trails true prevalence.

The United States remains the single largest national market, with 2026 demand estimated at about $720 million and a 2033 value approaching $1.1 billion as prophylaxis adoption remains high and specialty distribution remains highly organized. The country benefits from strong hemophilia treatment centers, advanced diagnosis, and consistent payer coverage for severe cases, although pricing pressure has intensified as insurers scrutinize product selection and dosing frequency. China is smaller on a per patient basis but one of the fastest expanding national markets, rising from roughly $210 million in 2026 toward $380 million by 2033 as diagnosis improves in tier 1 and tier 2 cities and provincial hospital procurement becomes more structured. Germany and Japan together form a high-value premium therapy cluster, with Germany near $145 million and Japan near $130 million in 2026, both growing steadily on the back of mature reimbursement systems and strong specialist-led care pathways.

India, South Korea, and Italy create a mixed picture of scale, access, and pricing discipline, with India at roughly $95 million in 2026 but rising quickly as screening and donor plasma infrastructure improve, while South Korea and Italy sit near $75 million and $90 million respectively, supported by concentrated hospital networks and high awareness among hematology specialists. France and the United Kingdom each hold important reimbursement-backed markets, estimated near $105 million and $98 million in 2026, though growth is more measured because treatment access is already relatively broad. Canada contributes about $72 million, while Mexico is near $58 million and Brazil around $110 million, with Brazil standing out in Latin America due to public-sector purchasing and growing specialist capacity. In these markets, investment has focused on supply security, centralized procurement, and broader diagnostic outreach, and Stats N Data estimates that local tender cycles now influence a larger share of annual volume than they did five years ago.

Turkey, Indonesia, and Vietnam are still underpenetrated but increasingly relevant, with 2026 market values of about $46 million, $39 million, and $34 million respectively, each expanding as hospital budgets and rare disease programs mature. Saudi Arabia and the United Arab Emirates are smaller in population but punch above their weight in value terms because of high treatment intensity and strong state-backed coverage, with 2026 market sizes near $41 million and $27 million. South Africa, Australia, and Thailand add further diversity, with Australia around $63 million due to strong access and specialist infrastructure, South Africa near $29 million, and Thailand close to $37 million as urban hospital systems broaden hemophilia management. Spain, the Netherlands, Poland, Malaysia, and Argentina together represent a layered mid-market segment, with Spain near $84 million, the Netherlands about $52 million, Poland around $47 million, Malaysia near $33 million, and Argentina roughly $31 million, all shaped by the balance between public reimbursement, hospital procurement, and uneven diagnostic reach.

By type, plasma-derived Factor IX Complex products still account for the larger share of market value in 2026, at roughly 58 percent, because they remain deeply embedded in established hospital pathways and in markets where cost discipline matters. Recombinant Factor IX products hold about 42 percent and are gaining share in premium systems where purity, predictable supply, and lower pathogen concern are valued, especially in the United States, Germany, Japan, and Australia. By application, prophylaxis represents about 61 percent of value, while on-demand treatment and perioperative use make up the balance, reflecting the long-term clinical preference for preventing joint damage rather than treating repeated bleeds. Regionally, North America leads value, followed by Europe, Asia Pacific, Latin America, and the Middle East and Africa, with the strongest future share gains expected in Asia Pacific and selected Gulf markets as access improves.

Several drivers are supporting demand, starting with more consistent diagnosis of hemophilia B and a clear clinical preference for reducing bleed frequency through prophylaxis. Aging patient cohorts in mature markets are increasing lifetime utilization, while children diagnosed earlier are staying in treatment longer and using more product over time. Public and private payers are also accepting higher annual treatment costs when they are tied to fewer hospitalizations, lower orthopedic burden, and better quality of life. A second driver is the gradual move toward supply diversification, where hospital systems want multiple sourcing options to reduce disruption, and this is encouraging procurement of both plasma-derived and recombinant products depending on local policy.

The main restraints remain price sensitivity, plasma supply dependence for part of the category, and the fact that many patients in lower-income systems are still not diagnosed or treated regularly. In several markets, treatment is constrained by central tendering and reimbursement ceilings, which suppresses per patient revenue even where clinical need is clear. Cold-chain handling, specialist prescribing requirements, and the need for hospital-based administration can also slow uptake outside major cities. Safety concerns have improved over time, but procurement teams remain cautious, particularly in systems that still remember historic blood product risks, and this makes adoption cycles longer than in many other specialty biologics.

Opportunities are strongest in underdiagnosed populations, emerging reimbursement programs, and the gradual shift toward more individualized factor replacement strategies. There is room for meaningful gains in India, Indonesia, Vietnam, Mexico, and parts of Africa where treatment coverage is still partial but registry quality is improving. Mid-sized private hospital systems are also becoming more important customers because they can adopt specialist therapy faster than public systems that face budget cycles and tender delays. Stats N Data sees a clear opening for manufacturers that combine education, patient support, and stable distribution, especially in countries where a small change in diagnosis rates can translate into outsized revenue growth.

The market’s biggest challenges are not simply clinical but operational, since many health systems struggle with forecasting demand for rare disease products that have high unit values and uneven usage patterns. Manufacturers must manage inventory carefully because expiry risk, procurement delays, and episodic bleeding events can all distort orders. Another challenge is product differentiation, as many buyers view Factor IX Complex mainly through reimbursement and service reliability rather than brand preference alone. In several countries, competition among suppliers has increased, but the market still rewards firms that can guarantee availability, support emergency fulfillment, and provide stable training for clinicians and pharmacists.

Technology trends are centered on improved purification, better virus inactivation, and tighter control over potency and consistency. Recombinant manufacturing continues to advance, while plasma fractionation systems are becoming more efficient and less wasteful, helping suppliers protect margins even when pricing pressure remains strong. Digital tracking of patient outcomes and inventory is becoming more common in high-income markets, which improves adherence monitoring and helps hospitals match stock to actual utilization. Another important trend is the integration of factor therapy into broader rare disease management platforms, where manufacturers offer education, infusion support, and treatment pathway tools alongside the product itself, making the commercial proposition more durable.

Regionally, North America will remain the value leader through 2033, but Europe will continue to matter because of its stable reimbursement base and strong specialist networks, especially in Germany, the United Kingdom, France, Italy, Spain, and the Netherlands. Asia Pacific is expected to post the fastest aggregate growth, driven by China, India, Japan, South Korea, Australia, Thailand, and Malaysia, where diagnosis expansion and hospital modernization are altering demand patterns. Latin America will grow more unevenly, with Brazil and Mexico ahead of Argentina, while the Middle East will benefit from Saudi Arabia and the United Arab Emirates due to better funding and concentrated centers of care. Across all regions, procurement sophistication is rising, and buyers increasingly compare not just price but continuity, clinical support, and delivery reliability.

Competition remains focused on a limited set of global manufacturers and regional suppliers with strong hospital channel access, deep regulatory experience, and dependable supply chains. The market is not crowded in the way common biologics are, but it is unforgiving because switching costs are high for patients and procurement teams, and loss of trust can quickly affect renewals. Companies compete on purity, consistency, service depth, tender execution, and the ability to support both prophylaxis and breakthrough bleed use without supply interruption. Mergers, licensing agreements, and regional manufacturing partnerships are likely to stay important as firms seek access to plasma, reduce logistics risk, and protect share in tender-driven markets.

The analytical approach behind this market view combines patient pool logic, treatment penetration assumptions, pricing normalization, and channel-level demand mapping across hospital, specialty pharmacy, and government procurement routes. The historical base was built by comparing adoption trends from 2019 to 2025, then translating 2026 country-level values into a 2033 scenario using realistic assumptions on diagnosis growth, reimbursement access, and product mix. The forecast also reflects how rare-disease demand behaves differently from mass therapies, with value growth often coming from deeper treatment intensity rather than fast patient expansion. For manufacturers and investors, the clearest strategy is to prioritize supply reliability, local reimbursement engagement, and targeted education in countries where diagnosis is still low but policy momentum is improving.

The Factor IX Complex market, integral to the field of hematology, is experiencing a significant transformation, driven by advancements in therapeutics and an increasing understanding of hemophilia B. Factor IX, a crucial protein in the blood coagulation process, plays a vital role in helping patients manage bleeding disorders. The global market for the Factor IX Complex encompasses a range of products aimed at treating individuals with deficiencies in Factor IX, particularly those suffering from hemophilia B. According to a recently published report by STATS N DATA, the Factor IX Complex market is poised for substantial growth, spurred by rising incidences of hemophilia, enhanced healthcare infrastructure, and a growing emphasis on personalized medicine.

Market size has witnessed a notable escalation in recent years, with historical data reflecting a robust trajectory of growth that has laid the groundwork for future developments. Projections indicate that the Factor IX Complex market is expected to expand significantly over the next few years, driven by an aging population and increasing demand for innovative treatment options. Key market drivers include advancements in biotechnology, the introduction of novel therapies, and ongoing research initiatives aimed at improving patient outcomes. However, challenges such as high treatment costs and regulatory hurdles may restrain growth, creating a complex landscape for market participants to navigate.

Innovation is a cornerstone of the current landscape, with numerous technological advancements opening doors to more effective and less invasive treatment methodologies. The emergence of gene therapies and next-generation therapeutics is offering new hope for hemophilia patients, shifting the focus toward longer-lasting and potentially curative options. Furthermore, emerging economies are presenting new opportunities for expansion, as increased healthcare accessibility and awareness pave the way for enhanced treatment solution uptake. In summary, the Factor IX Complex market stands at a pivotal juncture, driven by a blend of historical momentum, cutting-edge innovations, and shifting patient demographics, poised to meet the evolving needs of those affected by bleeding disorders and to fundamentally change the trajectory of hemophilia management.

The global business environment is constantly evolving, and keeping up with the latest trends in the FACTOR IX COMPLEX MARKETis essential for businesses aiming to succeed. Our detailed market research report by STATS N DATA serves as a crucial resource for investors and companies, offering comprehensive insights into the Global Factor Ix Complex Industry. This report goes beyond mere data analysis, providing advanced revenue projections, in-depth forecasts, and a thorough examination of future trends from 2026 to 2033. For decision-makers navigating this dynamic market, our report is an indispensable guide, helping craft strategies aligned with the market's anticipated growth and changes.

Market Overview and Historical Perspective

The report begins with a detailed overview of the Factor Ix Complex Market, focusing on its current size, scope, and structure. By leveraging extensive historical data, the report uncovers key insights that trace the market's evolution over time. Understanding past trends and market patterns gives stakeholders a solid foundation for predicting future developments in the Factor Ix Complex Market. This historical perspective is essential for identifying growth opportunities and innovative paths forward, allowing businesses to position themselves advantageously.

Future Insights and Market Projections

In addition to historical analysis, the report offers forward-looking insights into the future of the Factor Ix Complex Market. Expert forecasts and detailed analyses of emerging trends provide stakeholders with a clear view of the market's expected direction. By identifying key growth drivers, such as technological innovations and increasing demand across various sectors, the report outlines the factors propelling the market forward. It also considers potential challenges like regulatory changes and economic uncertainties, equipping stakeholders with the knowledge needed to adapt and thrive.

Market Segmentation

The Factor Ix Complex Market is segmented into various categories, including product type, application/end-user, and geography. Detailed segmentation is outlined as follows:

Type

• 500 IU Factor IX/Bottle (20ml)
• 1000 IU Factor IX/Bottle (40ml)

Application

• Prevent Bleeding Episodes in People with Factor IX Deficiency
• Treat Bleeding Episodes in People with Factor IX Deficiency
• Other

Each segment is thoroughly examined to understand its role and impact on overall market dynamics. This section evaluates the size and growth rate of each segment, helping stakeholders pinpoint areas with significant expansion potential. This segmentation analysis is crucial for identifying the market's key drivers and understanding which areas offer the most promise for future development.

Additionally, the report includes a market attractiveness analysis, assessing the appeal of each segment based on factors such as market potential, competitive intensity, and growth prospects. This analysis provides a comprehensive view of which segments present the best opportunities for investment and strategic initiatives, enabling stakeholders to allocate resources effectively.

Geographic Analysis

The report also delves into the geographical segmentation of the Factor Ix Complex Market, offering an in-depth analysis of major regions including North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Each region is assessed based on market size, growth rate, and key trends, providing stakeholders with valuable insights into regional dynamics and expansion opportunities. This geographical analysis is critical for understanding the global landscape of the Factor Ix Complex Market and tailoring strategies to fit specific regional markets.

Competitive Landscape

Companies profiled in this report are

• Grifols
• CSL Behring
• Alpha Therapeutic Corp
• Octapharma AG
• Baxter International Inc
• Hualan Biological Engineering
• Shanghai Raas Blood Products Co. Ltd
• China Biologic Products Holdings
• Inc

The competitive landscape of the Factor Ix Complex Market is characterized by vigorous competition among leading players, all vying to maintain and expand their market share. Our report offers a comprehensive overview of this competitive environment, profiling major companies and analyzing their market positions. This section includes detailed SWOT analyses for each key competitor, highlighting their strengths, weaknesses, opportunities, and threats. Understanding these dynamics is vital for stakeholders looking to refine their strategies and secure a competitive edge.

The report also explores strategic moves by key players, including mergers, acquisitions, partnerships, and new product developments. Staying updated on these activities helps stakeholders anticipate changes in the competitive landscape and adjust their strategies accordingly.

Furthermore, the report features a benchmarking analysis of key products and services within the Factor Ix Complex Market. This comparison sheds light on the performance and market positioning of various offerings, helping stakeholders identify best practices and areas for improvement. This analysis is crucial for stakeholders aiming to enhance their competitive positioning and sustain a strong market presence.

Recent Developments

Significant developments have recently shaped the Global Factor Ix Complex Market, including mergers, acquisitions, partnerships, and innovative product launches. Our report provides an in-depth analysis of these recent changes, offering stakeholders insights into how these activities have influenced the market's competitive dynamics.

Beyond mergers and acquisitions, the report highlights strategic alliances and partnerships formed between key players in the Factor Ix Complex Market. These collaborations are essential for driving innovation and expanding market reach, and understanding these dynamics can help stakeholders identify potential opportunities for partnership and growth.

Moreover, the report includes a detailed analysis of recent product launches and technological innovations within the Factor Ix Complex Market. This section spotlights the latest advancements and emerging trends, providing stakeholders with crucial information on new opportunities. Staying informed about these developments is key for stakeholders looking to maintain a competitive edge.

Technological Advancements and Future Disruptions

Technological advancements are a major driver of change in the Global Factor Ix Complex Market. Our report highlights the most impactful technological trends, showing how these innovations are reshaping the industry. This section offers a comprehensive overview of the latest technological developments, including breakthroughs in product design, manufacturing techniques, and digital technologies.

The report also examines the impact of these technological advancements on the Factor Ix Complex Market, exploring how they are altering industry dynamics and creating new opportunities for growth. This analysis is essential for stakeholders looking to leverage technology to enhance their competitive positioning and meet evolving market demands.

Additionally, the report provides insights into future technological innovations that have the potential to disrupt the market. These emerging technologies are poised to create new growth opportunities and challenges, and staying informed about these developments is crucial for stakeholders aiming to stay ahead of the competition.

Industry Dynamics and Market Structure

The report offers a detailed examination of the overall structure and dynamics of the Factor Ix Complex Market, helping stakeholders understand the industry's key components and their interactions. Understanding these elements is vital for identifying collaboration and innovation opportunities that drive market growth.

The report also explores the key factors influencing industry dynamics, including economic, regulatory, and technological aspects. By understanding these dynamics, stakeholders can develop strategies that align with the industry's overall structure and capitalize on emerging opportunities.

Moreover, the report provides insights into the evolving nature of the Factor Ix Complex Market?s value chain. This analysis follows the process from suppliers to end-users, highlighting where value is added at each stage. By optimizing the value chain, stakeholders can improve operational efficiency and secure a competitive advantage.

Porter's Five Forces Analysis

Our Factor Ix Complex Market report employs Porter's Five Forces Analysis to offer a strategic framework for understanding the competitive landscape. This analysis evaluates the bargaining power of buyers and suppliers, the threat of new entrants and substitute products, and the intensity of competitive rivalry. These insights are crucial for stakeholders looking to understand the factors that influence the industry's profitability and competitiveness.

The report also explores how these forces might evolve over time, providing stakeholders with insights into future competitive dynamics. By understanding these forces, stakeholders can develop strategies that enhance their market position and mitigate potential risks.

Value Chain Analysis

The Factor Ix Complex Market report includes a comprehensive value chain analysis, offering stakeholders a detailed understanding of the process from suppliers to end-users. This analysis highlights each phase of the value chain, showing where value is added and identifying potential areas for efficiency improvements or strategic adjustments. By optimizing the value chain, stakeholders can enhance their operational efficiency and secure a competitive edge.

In addition to mapping the value chain, the report explores the key drivers of value creation within the Factor Ix Complex Market. Understanding these drivers is critical for stakeholders seeking to maximize their return on investment and drive business growth.

Customer Preferences and Market Trends

Understanding customer preferences and market trends is vital for success in the Factor Ix Complex Market. The report identifies key consumer expectations and trends, providing clarity on what consumers value most in products and services. This section explores how these preferences are evolving, offering stakeholders insights into how they can tailor their offerings to meet changing consumer demands.

The report also examines the impact of these trends on the market, analyzing how shifts in consumer preferences are driving changes in the industry. By aligning their strategies with customer needs, stakeholders can improve customer satisfaction, build brand loyalty, and drive business growth.

Regulatory Landscape

The regulatory environment plays a critical role in shaping the Factor Ix Complex Market. Our report provides a comprehensive overview of the key regulations and standards that impact the industry. This section examines the legal and regulatory framework governing the market, giving stakeholders a clear understanding of the rules and guidelines they must follow.

The report also explores the implications of recent regulatory changes, evaluating how these modifications are shaping the market and affecting stakeholders. Understanding the regulatory landscape is essential for stakeholders looking to stay compliant and avoid potential legal complications.

Additionally, the report provides insights into potential future regulatory developments. Staying informed about these changes is crucial for stakeholders seeking to anticipate challenges and adjust their strategies accordingly.

Market Entry Strategies

Entering the Factor Ix Complex Market presents several challenges, including high barriers to entry and intense competition. This report identifies the main obstacles new entrants must overcome to successfully penetrate the market, such as significant capital requirements, stringent regulatory standards, and the presence of established competitors.

The report also outlines critical success factors for new entrants in the Factor Ix Complex Market, covering essential aspects like innovation, effective marketing strategies, strategic partnerships, and a strong value proposition. By focusing on these key elements, new entrants can effectively manage market complexities and improve their chances of success.

Additionally, the report offers strategic recommendations for market entry, providing practical advice on market positioning, customer acquisition strategies, and differentiation tactics. These strategies are tailored to help new entrants establish a strong market presence and gain a competitive edge in the Factor Ix Complex Market.

Economic Indicators and Risk Analysis

The report explores the impact of macroeconomic factors on the Factor Ix Complex Market, including GDP growth, inflation rates, and employment trends. This analysis offers stakeholders a comprehensive understanding of the broader economic environment and its influence on the market, supporting informed decision-making.

The report also examines the risks and uncertainties within the Factor Ix Complex Market, highlighting potential challenges to market stability and growth. These risks include economic volatility, regulatory shifts, and intense market competition. By understanding these risks, stakeholders can develop strategies to mitigate them and strengthen market resilience.

Additionally, the report provides specific strategies for mitigating identified risks. The section on impact assessment and mitigation offers actionable recommendations that help Factor Ix Complex Market participants manage risks effectively and maintain stability. By proactively addressing these risks, stakeholders can protect their interests and support sustainable growth.

Investment Analysis and Opportunities

This research evaluates key suppliers and distributors in the Factor Ix Complex Market, highlighting the primary entities involved in providing and distributing products. The report offers insights into their capabilities, reliability, and strategic significance within the supply chain. Understanding these dynamics allows stakeholders to optimize their operations and strengthen their market positions.

The report also identifies prime investment opportunities and offers strategic recommendations. It highlights areas with substantial potential for high returns, helping investors make informed decisions about resource allocation for maximum impact. Strategic investments in these high-potential areas can significantly increase profitability and stimulate market growth.

The report includes a comprehensive analysis of return on investment (ROI) and financial projections. This analysis is crucial for assessing the expected profitability of investments and developing informed financial strategies. Understanding these financial forecasts is essential for evaluating potential returns and associated risks of various investment avenues. By leveraging data-driven investment decisions, stakeholders can maximize their returns and achieve their financial objectives.

Moreover, the report includes feasibility studies for potential new projects or ventures. These studies evaluate the viability of new endeavors by analyzing market demand, cost estimates, and potential revenue. Such evaluations ensure that investors can make well-informed decisions about pursuing new opportunities. Engaging in feasible projects allows stakeholders to expand their market presence and drive business growth.

Technological and Innovation Insights

The Factor Ix Complex Market report explores emerging technologies and their potential impact on the market, highlighting how these advancements are setting the stage for the industry's future. This section focuses on innovations that could disrupt the market landscape, creating new opportunities for growth and innovation.

Additionally, the report provides a detailed analysis of the innovation landscape and research and development (R&D) activities within the Factor Ix Complex Market. It examines ongoing R&D efforts and the overall state of innovation, offering a comprehensive view of how companies are driving progress and maintaining competitiveness. This analysis is critical for understanding the role of innovation in market growth and identifying areas for strategic investment.

Furthermore, the report explores the potential of disruptive technologies within the Factor Ix Complex Market. These technologies have the capacity to reshape the industry, creating new opportunities and challenges. By staying informed about these emerging technologies, stakeholders can proactively adjust their strategies and leverage innovation to secure a competitive advantage.

Geographical Insights

The report delivers a thorough geographical analysis of the Factor Ix Complex Market, offering insights into regional trends and opportunities. This section covers key regions, including North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Understanding these regional dynamics is essential for identifying growth opportunities and tailoring strategies to specific markets.

Regional Highlights

The analysis also highlights regional trends and developments, emphasizing the most significant market drivers and challenges in each area. By understanding these regional dynamics, stakeholders can make informed decisions about market entry, expansion, and resource allocation.

Market Size and Regional Growth

The report examines the market size and growth rate across different regions, providing a clear view of which areas are experiencing the most rapid growth. This information is crucial for identifying key markets and planning strategic initiatives.

Emerging Markets and Strategic Opportunities

The report identifies emerging markets with high growth potential, offering strategic recommendations for capitalizing on these opportunities. Understanding these emerging markets is vital for stakeholders looking to expand their presence and tap into new growth areas.

FAQ

• What is the Global Factor Ix Complex Market size, and what growth rate can be expected during the forecast period?

• What are the key factors driving the growth of the Factor Ix Complex Market?

• What challenges and risks does the Factor Ix Complex Market currently face?

• Who are the major players in the Factor Ix Complex Market?

• What are the current trends influencing the shares of the Factor Ix Complex Market?

• What insights can be gleaned from applying Porter's Five Forces model to the Factor Ix Complex Market?

• What global expansion opportunities are available in the Factor Ix Complex Market?

Our comprehensive market research report on the Global Factor Ix Complex Market is an invaluable resource for investors, executives, and companies looking to deepen their understanding of the industry. With detailed analyses, actionable insights, and strategic recommendations, this report equips stakeholders with the knowledge they need to make informed decisions and capitalize on the opportunities within the Factor Ix Complex Market. We encourage you to leverage these insights to enhance your strategic planning and secure a competitive edge in this dynamic market.